Zoledronic acid
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Zoledronic acid and local guidelines before prescribing.
Mechanism
Bisphosphonate inhibiting osteoclasts.
Uses
Osteoporosis (annual infusion), hypercalcaemia of malignancy, Paget disease, bone metastases.
Dosing
- Hypercalcaemia | 0.9% saline 4–6 L in 24 hours, then zoledronic acid 4 mg IV
Endocrinology: Emergencies - Then zoledronic acid 4 mg IV over 15 minutes , or pamidronate 30–90 mg.
Endocrinology: Emergencies - Zoledronic acid Hypercalcaemia | 4 mg IV over 15 minutes, after rehydration.
Endocrinology: Emergencies - Avoid oral bisphosphonates if creatinine clearance is below about 35 mL/min, and zoledronic acid if below 35 mL/min.
Endocrinology: Bone Medicine
6 more dose entries from the chapters
- Zoledronic acid 4 mg IV over 15 minutes , or pamidronate 30–90 mg IV .
Endocrinology: Bone Medicine - As for the emergency: IV fluids , then zoledronic acid 4 mg (or pamidronate).
Endocrinology: Bone Medicine - Treat bone pain from active Paget's with a bisphosphonate. Zoledronic acid 5 mg IV as a single infusion is most effective, often giving years of remission. Ensure vitamin D is replete beforehand. Alternatives are oral risedronate or alendronate.
Endocrinology: Bone Medicine - Bone-targeted drugs to reduce skeletal events - zoledronic acid 4 mg IV every 3–4 weeks or denosumab 120 mg SC every 4 weeks (oncology doses). Note the higher ONJ risk at these doses.
Endocrinology: Bone Medicine - Zoledronic acid (osteoporosis, Paget's) | 5 mg IV over at least 15 minutes, once yearly for osteoporosis, or a single dose for Paget's. Correct vitamin D first; check renal function. Acute phase reaction.
Endocrinology: Bone Medicine - Zoledronic acid (hypercalcaemia, metastases) | 4 mg IV over 15 minutes after rehydration. Every 3–4 weeks for bone metastases or myeloma. Adjust for renal function.
Endocrinology: Bone Medicine
Side effects
Acute-phase reaction, hypocalcaemia, osteonecrosis of the jaw, atypical fracture, renal impairment.
Interactions
Aminoglycosides and loop diuretics increase hypocalcaemia; NSAIDs renal toxicity.
Contraindications and cautions
Hypocalcaemia, CrCl below 35
Monitoring
Calcium, creatinine
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid if CrCl below 35
Overdose and reversal
Supportive; calcium
Special advice
Correct vitamin D and calcium before infusion; dental review; paracetamol for flu-like reaction.
More from the textbook: uses, cautions and other points
- Zoledronic acid (IV, once a year for osteoporosis) - after hip fracture or if oral drugs aren't tolerated; acute-phase reaction (flu-like symptoms for 1–3 days), hypocalcaemia, kidney toxicity (check eGFR, hydrate). Also used IV for hypercalcaemia of malignancy and bone metastases.
Endocrine: Anatomy Physiology and Pharmacology - High risk: Oral bisphosphonate (alendronic acid or risedronate) first-line. If not tolerated, unsuitable or ineffective: IV zoledronic acid or denosumab. HRT is an option in younger postmenopausal women.
Endocrinology: Bone Medicine - If stopping, give a bisphosphonate - usually zoledronic acid about 6 months after the last denosumab dose - and monitor.
Endocrinology: Bone Medicine - Treatment: Alendronate, risedronate, zoledronic acid, denosumab (licensed in men, including on androgen deprivation), or teriparatide. Testosterone replacement for hypogonadism, unless contraindicated.
Endocrinology: Bone Medicine - Zoledronic acid | IV yearly; acute-phase reaction; hypercalcaemia of malignancy.
Endocrine: Anatomy Physiology and Pharmacology - Oral alendronate is unsuitable (eGFR under 35); zoledronic acid also needs adequate kidney function.
Endocrine: Anatomy Physiology and Pharmacology - After any anabolic course: Always follow with an antiresorptive (usually zoledronic acid, alendronate or denosumab) to consolidate the gains.
Endocrinology: Bone Medicine - Zoledronic acid: Review after 3 years ; continue to 6 years if still high risk.
Endocrinology: Bone Medicine
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (3 mentions)
- Endocrinology: Emergencies (3 mentions)
- Endocrinology: Bone Medicine (21 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Myeloma and Lymphoma (3 mentions)
- Oncology: Emergencies (4 mentions)
- Oncology: Urology and Genital cancers (1 mention)
- Oncology: Breast and Gynae Cancers (4 mentions)
- Rheumatology Anatomy Physiology Pharmacology (3 mentions)
- Medicine of the older adult.: Falls, syncope, mobility and fragility fractures (2 mentions)
- Clinical pharmacology and prescribing: Prescribing in special groups (2 mentions)
- Acute Medicine: Electrolytes, acid–base, AKI and metabolic emergencies (3 mentions)
- Clinical imaging: Musculoskeletal and trauma imaging (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)